Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34

Neuro-oncology
Douglas R StrotherAmar Gajjar

Abstract

The randomized controlled Pediatric Oncology Group study 9233 tested the hypothesis that dose-intensive (DI) chemotherapy would improve event-free survival (EFS) for children <3 years of age with newly diagnosed malignant brain tumors. Of 328 enrolled eligible patients, diagnoses were medulloblastoma (n = 112), ependymoma (n = 82), supratentorial primitive neuroectodermal tumor (sPNET, n = 38) and other malignant brain tumors (n = 96), and were randomized to 72 weeks of standard dose chemotherapy (Regimen A, n = 162) or DI chemotherapy (Regimen B, n = 166). Radiation therapy (RT) was recommended for patients with evidence of disease at completion of chemotherapy or who relapsed within 6 months of chemotherapy completion. Distributions of EFS for Regimens A and B were not significantly different (P = 0.32) with 2- and 10-year rates of 22.8% ± 3.3% and 15.4% ± 3.7%, and 27.1% ± 3.4% and 20.8% ± 3.8%, respectively. Thus, the study hypothesis was rejected. While distributions of EFS and OS were not significantly different between Regimens A and B for patients with medulloblastoma and sPNET, DI chemotherapy resulted in significantly improved EFS distribution (P = .0011) (2-year EFS rates of 42.1% vs. 19.6% with SD chemotherapy), but...Continue Reading

References

Jun 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N V Cheung, G Heller
Sep 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W M Hryniuk
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J GrillUNKNOWN French Society of Pediatric Oncology
Mar 11, 2005·The New England Journal of Medicine·Stefan RutkowskiJoachim Kuehl
Aug 2, 2005·The Lancet Oncology·Jacques GrillUNKNOWN French Society of Paediatric Oncology
Oct 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Russell GeyerUNKNOWN Children's Cancer Group
Jun 8, 2007·Pediatric Blood & Cancer·Robert P SandersAlberto Broniscer
Jul 24, 2007·The Lancet Oncology·Richard G GrundyUNKNOWN Children's Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee
Apr 4, 2009·The Oncologist·Lucie Lafay-Cousin, Douglas Strother
Oct 13, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R G GrundyUNKNOWN Children's Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee
Sep 3, 2011·Journal of Neurosurgery. Pediatrics·Mark Van PoppelAmar J Gajjar
Dec 3, 2011·Acta Neuropathologica·Michael D TaylorStefan M Pfister
Apr 25, 2012·Acta Neuropathologica·Catherine GodfraindDavid W Ellison

❮ Previous
Next ❯

Citations

Oct 1, 2005·Journal of Neuro-oncology·Thomas E Merchant, Maryam Fouladi
Sep 10, 2015·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Yuan Y ThompsonMichael D Taylor
Jul 5, 2015·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·C VigneronG Noël
Feb 19, 2015·Current Neurology and Neuroscience Reports·Lindsey M HoffmanMaryam Fouladi
Jun 24, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E Merchant
Nov 21, 2017·Neuro-oncology·Mohamed S AbdelBakiMark W Kieran
Feb 28, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E MerchantVijay Ramaswamy
Mar 14, 2019·Pediatric Blood & Cancer·Bryan J AgerMatthew M Poppe
Sep 13, 2019·Pediatric Blood & Cancer·Amardeep S GrewalChristine Hill-Kayser
Feb 28, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alyssa T ReddyAnnie Huang
May 12, 2020·The Journal of Pathology·Chantel CacciottiVijay Ramaswamy
Oct 28, 2015·Journal of Child Neurology·Nicholas A Vitanza, Sonia Partap
Jul 12, 2018·Current Oncology Reports·Patrick Sin-ChanAnnie Huang
Jan 29, 2020·Cancer Metastasis Reviews·Christina ColemanSabine Mueller
Oct 7, 2020·Journal of Neuro-oncology·Cody L NesvickDavid J Daniels
Jan 9, 2021·Frontiers in Oncology·Julie BennettUte Bartels

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J Russell GeyerChildren's Cancer Group
Journal of Pediatric Surgery
Deborah F BillmireChildren's Oncology Group
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Nancy TarbellLarry E Kun
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A J ProvisorJ S Miser
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Debra P LeePeter C Adamson
© 2021 Meta ULC. All rights reserved